AU676721B2 - Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof - Google Patents

Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof

Info

Publication number
AU676721B2
AU676721B2 AU61691/94A AU6169194A AU676721B2 AU 676721 B2 AU676721 B2 AU 676721B2 AU 61691/94 A AU61691/94 A AU 61691/94A AU 6169194 A AU6169194 A AU 6169194A AU 676721 B2 AU676721 B2 AU 676721B2
Authority
AU
Australia
Prior art keywords
ubiquitin
inhibitor
cleavage
mhc
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61691/94A
Other languages
English (en)
Other versions
AU6169194A (en
Inventor
Alfred L. Goldberg
Kenneth L Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Dana Farber Cancer Institute Inc
Original Assignee
Harvard College
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Dana Farber Cancer Institute Inc filed Critical Harvard College
Publication of AU6169194A publication Critical patent/AU6169194A/en
Application granted granted Critical
Publication of AU676721B2 publication Critical patent/AU676721B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU61691/94A 1993-02-10 1994-01-27 Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof Ceased AU676721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1606693A 1993-02-10 1993-02-10
PCT/US1994/001183 WO1994017816A1 (en) 1993-02-10 1994-01-27 Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
US016066 1996-04-23

Publications (2)

Publication Number Publication Date
AU6169194A AU6169194A (en) 1994-08-29
AU676721B2 true AU676721B2 (en) 1997-03-20

Family

ID=21775196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61691/94A Ceased AU676721B2 (en) 1993-02-10 1994-01-27 Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof

Country Status (5)

Country Link
EP (1) EP0684829A4 (de)
JP (1) JPH08507754A (de)
AU (1) AU676721B2 (de)
CA (1) CA2155554A1 (de)
WO (1) WO1994017816A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
JP4503182B2 (ja) 1998-10-20 2010-07-14 ミレニアム・ファーマシューティカルズ・インコーポレイテッド プロテアソーム・インヒビター薬物作用のモニター方法
JP2002105080A (ja) * 2000-09-29 2002-04-10 Microbial Chem Res Found 生理活性物質パネポフェナンスリンとその製造法
KR20060026052A (ko) 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
JP5783659B2 (ja) 2009-12-22 2015-09-24 セファロン、インク． プロテアソーム阻害剤およびその調製、精製および使用のための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390629A (en) * 1981-03-30 1983-06-28 President And Fellows Of Harvard College Polypeptide degrading enzymes
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

Also Published As

Publication number Publication date
CA2155554A1 (en) 1994-08-18
EP0684829A1 (de) 1995-12-06
EP0684829A4 (de) 1997-05-21
AU6169194A (en) 1994-08-29
WO1994017816A1 (en) 1994-08-18
JPH08507754A (ja) 1996-08-20

Similar Documents

Publication Publication Date Title
US5759994A (en) Recombinant thrombin receptor and related pharmaceuticals
AU676721B2 (en) Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
CA2219964A1 (en) Polypeptide capable of binding interleukin-18 and uses therof
AU721194B2 (en) Thrombin receptor homolog
US7214772B2 (en) Sialoadhesin family member-2 (SAF-2)
US6451759B1 (en) Noncleavable Fas ligand
WO1998002579A1 (en) Regulation of apoptosis and in vitro model for studies thereof
WO1997014797A9 (en) Cystatin m, a novel cysteine proteinase inhibitor
WO1998002579A9 (en) Regulation of apoptosis and in vitro model for studies thereof
AU732547B2 (en) Novel cyclin-selective ubiquitin carrier polypeptides
US6558900B2 (en) Regulation of apoptosis and in vitro model for studies thereof
WO1993009808A1 (en) METHODS FOR DETECTING AND ISOLATING uPA-R AND INHIBITING THE BINDING OF uPA TO uPA-R
US7176178B1 (en) Nuclear targeting by means of bacterial proteins
US6180379B1 (en) Cyclin-selective ubiquitin carrier polypeptides
US6833355B1 (en) Use of protein H as cytostatic agent
AU727222B2 (en) Regulation of apoptosis and in vitro model for studies thereof
WO2000023590A2 (en) INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
MXPA97009746A (en) Homologo de receptor de tromb
JP2002523069A (ja) ＲＡＭＰ２ａ：受容体活性改変タンパク質‐２ａ
MXPA98008070A (en) Novedous polypeptides carriers of selected cybinetines of cicl